Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.20

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been assigned a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $30.20.

Several equities research analysts have weighed in on ATXS shares. Cantor Fitzgerald reissued an “overweight” rating and set a $49.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, September 17th. Citigroup reaffirmed an “outperform” rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. JMP Securities upped their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 13th. Finally, HC Wainwright increased their target price on shares of Astria Therapeutics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS opened at $7.51 on Friday. The company has a market cap of $423.86 million, a P/E ratio of -3.74 and a beta of 0.42. The firm’s fifty day moving average is $6.79 and its two-hundred day moving average is $5.76. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $12.88.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.04. As a group, analysts forecast that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC increased its stake in shares of Astria Therapeutics by 503.7% in the first quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company’s stock worth $493,000 after acquiring an additional 76,961 shares during the period. Deutsche Bank AG grew its position in Astria Therapeutics by 54.3% during the fourth quarter. Deutsche Bank AG now owns 39,744 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 13,986 shares during the period. Hsbc Holdings PLC grew its position in Astria Therapeutics by 70.3% during the first quarter. Hsbc Holdings PLC now owns 32,808 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 13,545 shares during the period. GAMMA Investing LLC grew its position in Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,971 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Astria Therapeutics by 13.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company’s stock valued at $567,000 after buying an additional 7,756 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.